Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CD74 | P04233 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8164538 | 0.88 | CA5A (0.64) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL2594483 | 0.87 | ALDH1A1 (0.67) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL8151152 | 0.86 | CA5A (0.73) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL29113901 | 0.86 | CYP2C19 (0.53) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL8157880 | 0.86 | CA5A (0.68) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL6738882 | 0.85 | CA5A (0.74) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL17283074 | 0.84 | CYP2C19 (0.60) | CA5ACYP2C19ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL15838648 | 0.84 | CA5A (0.69) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL460913 | 0.83 | CA5A (0.76) | CA5ACYP2C19ALDH1A1LMNAKLKB1 | |
| SCHEMBL15838652 | 0.82 | CA5A (0.75) | CA5ACYP2C19ALDH1A1LMNAKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2640711-B1 | IMPROVED PROCESS FOR THE PREPARATION OF RUFINAMIDE | DAVULURI RAMAMOHAN RAO (IN) | 2015-10-14 | — | — | EP | claimed |
| US-8871945-B2 | Process for preparation of rufinamide | DAVULURI RAMAMOHAN RAO (US) | 2014-10-28 | — | — | US | claimed |
| US-20130184469-A1 | PROCESS FOR PREPARATION OF RUFINAMIDE | DAVULURI RAMAMOHAN RAO (US) | 2013-07-18 | — | — | US | claimed |
| US-8183269-B2 | Process for the preparation of rufinamide | CIPLA LIMITED (IN) | 2012-05-22 | — | — | US | claimed |
| US-20110207938-A1 | Process for the Preparation of Rufinamide | CIPLA LIMITED (IN) | 2011-08-25 | — | — | US | claimed |
| EP-2334653-A1 | PROCESS FOR THE PREPARATION OF RUFINAMIDE | Cilpa Limited (IN) | 2011-06-22 | — | — | EP | claimed |
| WO-2010043849-A1 | PROCESS FOR THE PREPARATION OF RUFINAMIDE | CIPLA LIMITED (IN) | 2010-04-22 | — | — | WO | claimed |
| CN-117105873-A | Preparation method of rufeamide intermediate | 宿州亿帆药业有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117050027-A | Preparation method of rufeamide impurity reference substance | 宿州亿帆药业有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-9771335-B2 | Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771335-B2 | Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| WO-2017023739-A1 | DERIVATIVES OF RUFINAMIDE AND THEIR USE IN INHIBTION OF THE ACTIVATION OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20170029382-A1 | DERIVATIVES OF RUFINAMIDE AND THEIR USE IN INHIBTION OF THE ACTIVATION OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | AES GLOBAL HOLDINGS, PTE. LTD. (SG) | 2017-02-02 | — | — | US | disclosed |
| WO-2010043849-A1 | PROCESS FOR THE PREPARATION OF RUFINAMIDE | CIPLA LIMITED (IN) | 2010-04-22 | — | — | WO | disclosed |
| US-20040167186-A1 | Use of certain crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide in treating epilepsy | PORTMANN ROBERT (CH) | 2004-08-26 | — | — | US | disclosed |
| US-6740669-B1 | VARYING SOLVENT AND/OR DURATION OF RECRYSTALLIZATION; RUFINAMIDE ORANGE BOOK LISTED PATENT | NOVARTIS AG (CH) | 2004-05-25 | — | — | US | disclosed |
| US-20030125568-A1 | Crystal modifications of 1-(2,6-difluoro benzyl)-1H-1,2,3-triazole-4-carboxamide | NOVARTIS PHARMA AG (CH) | 2003-07-03 | — | — | US | disclosed |
| EP-0994863-B1 | CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC | NOVARTIS AG (CH) | 2003-02-19 | — | — | EP | disclosed |
| EP-0994863-A1 | CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC | Novartis AG (CH) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998056772-A1 | CRYSTAL MODIFICATION OF 1-(2,6-DIFLUOROBENZYL)-1H-1,2,3--TRIAZOLE-4-CARBOXAMIDE AND ITS USE AS ANTIEPILEPTIC | NOVARTIS AG (CH) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125568-A1 | Crystal modifications of 1-(2,6-difluoro benzyl)-1H-1,2,3-triazole-4-carboxamide | CYP2F1, SULT2A1, CYP1B1 | CA5A 88/4885CYP2C19 23/4885ALDH1A1 113/4885 |
| US-20170029382-A1 | DERIVATIVES OF RUFINAMIDE AND THEIR USE IN INHIBTION OF THE ACTIVATION OF HUMAN VOLTAGE-GATED SODIUM CHANNELS | SCN1A, HVCN1, SCN1B | CA5A 1974/4885CYP2C19 2904/4885ALDH1A1 616/4885 |
| US-20040167186-A1 | Use of certain crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide in treating epilepsy | SCN1A, CYP2F1, CA3 | CA5A 42/4885CYP2C19 78/4885ALDH1A1 311/4885 |
| US-20110207938-A1 | Process for the Preparation of Rufinamide | AZI2, F13A1, RTN3 | CA5A 2300/4885CYP2C19 239/4885ALDH1A1 323/4885 |
| US-20130184469-A1 | PROCESS FOR PREPARATION OF RUFINAMIDE | CYP4F8, CYP3A4, CYP4F3 | CA5A 1032/4885CYP2C19 64/4885ALDH1A1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.